Education

  2. Home
  3. Education
  4. Pharmacist
Results 1 - 35 of 35
9916-cme-icon
Personalized Medicine for Improving Asthma Care: An Animated Video Series
9916-0005-icon
Discussions with Patients to Optimize Asthma Control
9916-0004_treatment
Who Should be Targeted For Treatment With Biologic Therapy?
9916-0003_endotypes
Endotypes and Phenotypes in Asthma
9916-0002_moa3
Mechanisms of Action of Biologic Therapies for Severe Asthma
9916-0001_meds
Approved Medications for the Treatment of Severe Asthma
9907-0006_shared
Engage Your Patients in Shared Decision-Making
9907-0005_cardio
Is It IPF or Cardiovascular Disease?
9907-0004_ip
Interstitial Pneumonia with Autoimmune Features
9907-0003_pf-ild
How to Identify Progressive Fibrosing ILD
9907-0002_ctd
When Is It a Connective Tissue Disease?
9907-0001_guidelines
How to Use IPF Guidelines to Make a Diagnosis
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Search